Black mould and rusty equipment lands Indian TB drug supplier WHO warning

By Dan Stanton contact

- Last updated on GMT

WHO's headquarters in Geneva, Switzerland
WHO's headquarters in Geneva, Switzerland

Related tags: Good manufacturing practice

An Indian TB drugmaker has been hit with a WHO Notice of Concern but an independent audit carried out by its customer Svizera Europe disputes the GMP violations raised.

A Notice of Concern (NOC) is implemented by the World Health Organisation (WHO) to facilities it deems has violated Good Manufacturing Practices (GMP), and following an inspection in June, the agency’s Prequalification Team has this week issued such a warning to a site in Navi, Mumbai.

The facility is run by Svizera Labs Private Limited – a subsidiary of Maneesh Pharmaceuticals – and manufactures a number of anti-tuberculosis drugs for Svizera Europe which, despite the namesake, is an independent supplier and distributor of infectious disease treatments to the WHO.

According to the Notice​, the firm failed to provide adequate controls to stop the contamination of products, with inspectors observing uneven floor, crumbling walls, and black mould inside a drain which also held stagnant water.

Furthermore, granulation equipment was found to be scratched, chipped and rusted in parts while the rubber seals had many pieces missing.

Other critical deviations from the WHO GMP standards observed at the site, included: issues around the integrity of dissolution test results and sample data, failure in conducting stability tests in line with protocols, and failures in maintaining equipment use records.

Independent Audit

The pre-qualified products made at the Mumbai facility are supplied to Svizera Europe, where final batch release is carried out.

We spoke to Anuschka Ploos van Amstel, Quality manager at The Netherlands-based company, who said Svizera Europe is disputing the WHO’s findings.

We disagree with the content of the report and the decision of WHO/PQ to publish such an NOC,”​ she told in-Pharmatechnologist.com.

“Based on the initial report … our QP initiated a full WHO GMP audit by an independent company - SGS Chennai - with a focus on the observations made by WHO/PQ whereas the conclusion is that the said plant is fully compliant with WHO GMP.”

At this stage, the NOC will not affect current pre-qualified products, van Amstel confirmed, though the firm cannot submit new dossiers to pre-qualification until the warning has been lifted.

Related news

Show more

Related products

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us

Products

View more

Webinars